Skip to main content

Table 1 Characteristics of the patients in the exploration and validation cohorts

From: Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients

Patient characteristic Initial exploration cohort (n = 46) Clinical validation cohort (n = 147)
Gender (male/female) 34*/12* 79*/68*
Age (years) 61.5 ± 8.8 [43–81] 59.4 ± 12.1 [20–87]
Weight (kg) 67.0 ± 11.2 [46.3–90.7] 63.8 ± 11.7 [38.3–105.0]
Height (cm) 166.4 ± 7.4 [152.6–184.4] 164.3 ± 8.7 [139.0–185.2]
Blood glucose 5.7 ± 1.1 [4.1–9.1] 5.9 ± 1.4 [3.7–10.8]
BMI (kg/m2) 24.1 ± 3.5 [17.4–33.1] 23.6 ± 3.6 [15.5–36.0]
Injected dose (MBq) 125.9 ± 21.1 [85.1–174.4] 119.7 ± 22.3 [73.1–216.0]
Injected dose per unit weight (MBq/kg) 1.88 ± 0.09 [1.73–2.15] 1.88 ± 0.10 [1.67–2.18]
Uptake time (min) 64.7 ± 17.2 [40–106] 73.4 ± 17.5 [40–115]
Lesion counts (lesion/patient) 1.6 ± 0.8 [1–4] 1.6 ± 1.1 [1–8]
Lesion short diameter (mm) 15.8 ± 12.8 [4.9–85.5] 20.8 ± 18.6 [4.0–120.4]
  1. Unless otherwise specified, data are presented as mean ± SD [range: min to max]
  2. *Data are numbers of patients. BMI = body mass index